-
Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum AB (publ) Year-End Report 2019
18 Feb 2020Immunicum AB (publ) Presents Updated Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer at ASCO-SITC Clinical Immuno-Oncology Symposium
06 Feb 2020Immunicum AB (publ) Announces Publication of Abstracts for the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
03 Feb 2020
News
-
Immunicum Article in BioStock
12 Feb 2020 -
RedEye Interview with COO, Sijme Zeilemaker
12 Feb 2020 -
Edison Coverage from 7 February 2020
7 Feb 2020 -
Phase II MERECA Updated Results Video
6 Feb 2020 -
Corporate Presentation – February 2020
6 Feb 2020
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to target solid tumors.
Learn more
